Semaglutide for Weight Loss: Comprehensive Meta-Analysis Confirms Efficacy With or Without Diabetes
Systematic review and meta-analysis of RCTs confirms semaglutide effectively reduces body weight in overweight/obese adults both with and without type 2 diabetes, with a manageable safety profile.
Quick Facts
What This Study Found
Meta-analysis of RCTs confirmed semaglutide significantly reduces body weight in overweight/obese adults with or without T2DM compared to placebo, with consistent effects across multiple anthropometric and metabolic outcomes.
Key Numbers
PROSPERO-registered systematic review. Multiple RCTs included from comprehensive database search.
How They Did This
PROSPERO-registered systematic review and meta-analysis. Searched Embase, PubMed, and Cochrane Library for RCTs of semaglutide in overweight/obese adults. Evaluated body weight change, BMI, waist circumference, and safety outcomes.
Why This Research Matters
Establishes the comprehensive evidence base for semaglutide in weight management regardless of diabetes status, supporting its regulatory approval and clinical use for obesity as a standalone condition.
The Bigger Picture
Semaglutide has transformed obesity treatment from a niche area to a mainstream medical approach. This meta-analysis consolidates the evidence that was available from individual trials, providing the strongest possible synthesis for clinical guidelines and payer decisions.
What This Study Doesn't Tell Us
Specific numerical results weren't available in the abstract portion reviewed. Individual trial heterogeneity in doses, durations, and populations may affect pooled estimates. Publication bias is possible.
Questions This Raises
- ?What is the optimal semaglutide dose for weight loss in patients without diabetes?
- ?How does weight loss magnitude differ between diabetic and non-diabetic subgroups?
- ?What is the rate of weight regain after semaglutide discontinuation across these trials?
Trust & Context
- Key Stat:
- Effective with or without diabetes Meta-analysis confirms semaglutide's weight loss efficacy across RCTs regardless of T2DM status
- Evidence Grade:
- Strong evidence from a registered systematic review and meta-analysis of randomized controlled trials — the highest tier of clinical evidence.
- Study Age:
- Published in 2024; provides a current synthesis of semaglutide weight loss trial data.
- Original Title:
- Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis.
- Published In:
- Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 29, 60 (2024)
- Authors:
- Yang, Liu(4), Duan, Xueyu, Hua, Peng, Wu, Shilin, Liu, Xiaobo
- Database ID:
- RPEP-09587
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Does semaglutide work for weight loss even if I don't have diabetes?
Yes. This meta-analysis confirms that semaglutide effectively reduces body weight in overweight and obese adults regardless of whether they have type 2 diabetes. The 2.4 mg dose (Wegovy) is specifically approved for weight management.
How much weight can I expect to lose on semaglutide?
Individual results vary, but clinical trials have shown average weight reductions of 10-15% of body weight with semaglutide 2.4 mg. This meta-analysis confirmed consistent weight loss benefits across multiple studies.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09587APA
Yang, Liu; Duan, Xueyu; Hua, Peng; Wu, Shilin; Liu, Xiaobo. (2024). Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis.. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 29, 60. https://doi.org/10.4103/jrms.jrms_693_23
MLA
Yang, Liu, et al. "Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis.." Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2024. https://doi.org/10.4103/jrms.jrms_693_23
RethinkPeptides
RethinkPeptides Research Database. "Effectiveness and safety of semaglutide in overweight/obese ..." RPEP-09587. Retrieved from https://rethinkpeptides.com/research/yang-2024-effectiveness-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.